ESPERION THERAPEUTICS INC

Esperion Therapeutics, Inc. is a biopharmaceutical company based in the United States, not in India. Its headquarters are located in Ann Arbor, Michigan, USA.

The company focuses on the development and commercialization of innovative oral, once-daily, non-statin medicines designed to lower low-density lipoprotein cholesterol (LDL-C). Its mission is to provide new treatment options for patients at high risk for cardiovascular disease who require additional LDL-C lowering. Their key products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe).

Regarding whether it is a factory or a trader, Esperion Therapeutics, Inc. is primarily a biopharmaceutical developer and marketer. While it does not typically own and operate large-scale manufacturing facilities, it is responsible for the research, development, clinical trials, regulatory approval, and commercialization of its proprietary pharmaceutical products. The actual manufacturing of its drugs is generally outsourced to contract manufacturing organizations (CMOs) under its strict quality control and supervision. Therefore, it functions as a creator and producer of pharmaceutical goods through its development and commercialization activities, rather than solely a trader of existing products.

Esperion Therapeutics Inc. does not directly produce or sell any products in India. The company is primarily focused on the United States market and, through partnerships, in Europe and other regions. Its main products, NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), are not directly manufactured or sold by Esperion Therapeutics Inc. in India.